Endocrinology 151 , 14731486 (2010)
Overall Adverse Event Rates Dose Group Any Adverse Event (%) GI Adverse Events (%) Discontinuation Due to AE (%) Placebo 72.1% 32.6% 0% 1 mg 88.6% 48.6% 2.9% 4 mg (escalated) 88.6% 60.0% 5.7% 4 mg (single dose) 90.9% 63.6% 6.1% 8 mg (escalated) 87.5% 57.5% 5.0% 8 mg (single dose) 88.6% 62.9% 5.7% 12 mg (escalated) 97.2% 66.7% 8.3% Source: Jastreboff AM, Kaplan LM, Fras JP, et al
RaFoSA: random forests secondary structure assignment for coarse-grained and all-atom protein systems

Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School BRAIN-TO Lab, Techna Institute, University Health Network Brigham and Womens Hospital Brigham and Womens Hospital, Harvard Medical School Brigham and Women's Hospital Brigham and Women's Hospital , Harvard Medical School Brigham and Women's Hospital , Harvard Medical School, Brigham and Women's Hospital / Harvard Medical School Brigham and Women's Hospital, Harvard Medical School Brigham and Women's Hospital/Harvard Medical School Brigham and Women's Hospital/Harvard University Brigham Young University Brighams and Women Hospital Brighton and Sussex Medical School Brighton BodyTalk Bristol Myers Squibb British Columbia Cancer Research Centre Brno University of Technology Brno University of Technology, Faculty of Electrical Engineering and Communication Brown University Bruker BioSpin MRI GmbH Bruker Japan K.K

Nutrition Aim for a modest calorie deficit of five to ten percent below maintenance or a protein targeted intake of about 1.2 to 1.6 grams per kilogram of body weight to preserve muscle
Obesity and thyroid functions, mutual interactions Obesity a disease recognized by the WHO as the most dangerous chronic disease, if untreated leads to cardiovascular diseases, DM2, metabolic syndrome, endocrine disorders and an increased risk of some types of cancer